Skip to main content
Search

Fred Hutch Cancer Center

4 related articles

Subscribe to updates
  1. bioRxiv

    A single-cell simulator with a dial for batch strength: scDeepSim varies batch effects and trajectory geometry on demand

    Benchmarking single-cell methods has been limited by costly annotation of real data and by datasets that capture only one observed condition. scDeepSim encodes expression into latent subvectors assigned to cell type, batch and residual variation, learns their distribution with latent diffusion, and at generation time modifies only the target subvector, imposing batch effects or constructing branching trajectories at user-set strengths. On scIB human pancreas data at intervention strength α=1, the structured model reached a mean cell-type silhouette width of 0.519 versus 0.432 for a plain variational autoencoder.

  2. bioRxiv

    DE-Rigor-Agent screens differential-expression methods before running them, keeping assumption mismatches from inflating FDR

    In bulk RNA-seq differential expression, general-purpose LLM agents tend to pick DESeq2 or edgeR without checking whether those methods' statistical assumptions fit the data at hand. DE-Rigor-Agent splits the analysis into input standardization, method filtering and method execution, and before running anything it evaluates six common methods against expert-curated method cards and dataset-specific diagnostics, recording why each is kept or excluded. Across 140 simulated datasets its filtering decisions largely matched the incompatibilities built into the simulations and stayed stable across random seeds, while two Codex baselines chose DESeq2 or edgeR for nearly all datasets.

  3. medRxiv

    Cancer side effects can be forecast from routine labs: SPARC holds up across 11 hospitals

    Predicting cancer treatment side effects has long relied on static nomograms built from a handful of variables. SPARC instead models longitudinal sequences of blood counts, metabolic panels and vital signs, pretraining on 101,920,379 measurements from 224,047 patients and then fine-tuning for mortality, anemia, neutropenia, febrile neutropenia, acute kidney injury and liver toxicity. It matched or led comparison models on held-out, prospective and multi-hospital cohorts, and its predicted risk strata identified patients most likely to benefit from G-CSF prophylaxis.

  4. Cancer

    CIBMTR real-world data: about one-third of multiple myeloma patients receiving cilta-cel are frail, with 12-month PFS of 62.7% and OS of 72.8% and doubled ICANS risk

    Using Center for International Blood and Marrow Transplant Research registry data, this study evaluated 541 patients with relapsed/refractory multiple myeloma who received commercial cilta-cel between March 2022 and December 2023 and found that 183 (33.8%) were frail by an adapted simplified frailty score; overall response rates were comparable (82.8% vs. 88.5%), but frail patients had worse 12-month progression-free survival (62.7% vs. 75.9%) and overall survival (72.8% vs. 90.4%) and more any-grade ICANS (32.2% vs. 17.6%), with frailty independently predicting worse PFS (HR 1.67), OS (HR 2.46), and any-grade ICANS (OR 2.01) on multivariable analysis.

You’re all caught up